Article
Developments in targeted therapy in melanoma.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology - 1 Mar 2017
Amann V C, Ramelyte E, Thurneysen S, Pitocco R, Bentele-Jaberg N, Goldinger S M, Dummer R, Mangana J
Abstract excerpt
Melanomas are disease entities driven in part by the mitogen activated protein kinase (MAPK) pathway. The TCGA network recently defined four genetic subtypes based on the most prevalent significantly mutated genes, including mutant BRAF, mutant RAS (N/H/K), mutant NF1, and Triple wild-type melanoma (harboring none of the aforementioned mutations, but instead includes KIT, GNA and GNAQ mutations). The successful...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.